Tuberculosis Treatment in Patients with Comorbidities

Young Ae Kang, M.D.
Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Tuberculosis is a significant infectious problem in elderly patients with comorbidities in Korea. The age-associated diseases such as malignancy and diabetes mellitus may increase the risk of tuberculosis in this population. The medication treatments of tuberculosis in patients with comorbidities can cause adverse reactions to antituberculosis drugs and inadequate treatment responses. Thus, clinicians must carefully monitor the toxicity of antituberculosis therapy and the efficacy of treatment in patients with comorbidities.

Keywords: Tuberculosis; Therapeutics; Comorbidity

Introduction

Tuberculosis is a significant infectious problem in elderly patients with comorbidities in Korea. The incidence of tuberculosis is increasing in older patients, and some have multiple comorbidities. This review summarizes the treatment of tuberculosis in patients with comorbidities including hepatic disease, chronic kidney disease, solid-organ transplantation, and solid malignant disease. This review is based on the Korean Guidelines for Tuberculosis, first edition, 2011

Hepatic Disease

Drug-induced liver injury (DILI) is a problem associated with the treatment of tuberculosis. Chronic liver disease is known to increase the risk of DILI. DILI in patients with advanced liver disease is potentially serious, even life-threatening. Thus, clinicians must carefully monitor hepatic function in patients with liver disease during the treatment of tuberculosis. The choice of the treatment regimen used in the setting of liver disease depends on the severity of both the liver disease and the tuberculosis.

Lee et al. reported that tuberculosis treatment in hepatitis B surface antigen (HBsAg)-positive inactive carriers can be performed in the usual manner, using standard short-course regimens of isoniazid, rifampin, ethambutol, and/or pyrazinamide with careful monthly monitoring of liver function. In that study, the authors showed that DILI occurred more frequently in HBsAg carriers (9 of 110 carriers, 8%) than in control subjects (4 of 97 controls, 4%). However, after the recovery of liver function, isoniazid and rifampin were successfully reintroduced as therapy. Park et al. reported on the treatment of tuberculosis in patients with chronic hepatitis and cirrhosis. In that study, the authors showed that hepatotoxic antituberculosis drugs might be safely used in patients with chronic liver disease, including compensated cirrhosis, if the number of hepatotoxic drugs used was appropriately adjusted.

Renal Insufficiency and End-Stage Renal Disease

Renal insufficiency complicates the treatment of tuberculosis because some antituberculosis drugs are cleared by the
Kidney. Management may be further complicated by the removal of some antituberculosis drugs via hemodialysis. Thus, clinicians should carefully monitor the potential development of drug-induced toxicity and the efficacy of antituberculosis treatment in patients with renal insufficiency. Some antituberculosis drugs require adjustment of their dosing and administration time intervals. Vitamin B6 should be given to these patients to prevent peripheral neuropathy due to isoniazid. The recommendations for adjustment of antituberculosis drug are shown in Table 2 and Table 3.

Table 1. Possible regimen of antituberculosis treatment in patients with hepatic disease*

| Underlying hepatic disease                          | Possible regimen                                                                 |
|------------------------------------------------------|-----------------------------------------------------------------------------------|
| Inactive HBsAg carrier                                | Standard short-course regimen                                                     |
| Inactive HCV carrier                                  | 1) 6HREZ/4HR(E)                                                                  |
| Past history of acute hepatitis                       | 2) 9HRE                                                                          |
| Alcohol drinker                                       | Monitor liver function                                                           |
| Chronic liver disease with stable liver function      | 9HRE                                                                             |
| Advanced liver disease                                | 1) Two hepatotoxic drugs                                                          |
| Unstable liver function                               | 9HRE                                                                             |
| Hepatic encephalopathy                                | 6-9 REZ                                                                          |
|                                                      | 2HRES/6HR                                                                        |
|                                                      | 2) One hepatotoxic drug                                                          |
|                                                      | 12-18 RE/FQ/CS/injectables                                                       |
|                                                      | 2HES/10HE                                                                        |
|                                                      | 3) No hepatotoxic drugs                                                          |
|                                                      | 18-24 E/FQ/CS/injectables                                                       |

*Based on the Korean guidelines for tuberculosis, 1st edition (2011), Treatment of tuberculosis guidelines, 4th edition (2010), and American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis (2003).

HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; H: isoniazid; R: rifampin; E: ethambutol; Z: pyrazinamide; S: streptomycin; FQ: fluoroquinolone; CS: cycloserine.

Table 2. Dosing recommendations for adult patients with reduced renal function and for adult patients undergoing hemodialysis*

| Drug              | Change in frequency | Recommended dose and frequency for patients with Ccr of <30 mL/min or patients undergoing hemodialysis |
|-------------------|---------------------|-----------------------------------------------------------------------------------------------------|
| Isoniazid         | No change           | 300 mg once daily                                                                                    |
| Rifampin          | No change           | 600 mg once daily                                                                                    |
| Pyrazinamide      | Yes                 | 25–35 mg/kg three times per week                                                                      |
| Ethambutol        | Yes                 | 15–25 mg/kg three times per week                                                                      |
| Levofloxacin      | Yes                 | 750–1,000 mg three times per week                                                                     |
| Moxifloxacin      | No change           | 400 mg once daily                                                                                    |
| Cycloserine       | Yes                 | 250 mg once daily or 500 mg three times per week                                                      |
| Ethionamide       | No change           | 250–500 mg once daily                                                                               |
| p-Aminosalicylic acid | No change          | 4 g twice daily                                                                                      |
| Streptomycin      | Yes                 | 12–15 mg/kg two or three times per week                                                               |
| Capreomycin       | Yes                 | 12–15 mg/kg two or three times per week                                                               |
| Kanamycin         | Yes                 | 12–15 mg/kg two or three times per week                                                               |
| Amikacin          | Yes                 | 12–15 mg/kg two or three times per week                                                               |

*Reprinted from Blumberg et al. Am J Respir Crit Care Med 2003;167:603-62, with permission of the American Thoracic Society. Copyright © 2014 American Thoracic Society; reprinted from Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention.

Ccr: creatinine clearance.
TB in patients with comorbidities

Solid-Organ Transplant

The risk for tuberculosis in patients with solid-organ transplantation is estimated to be 20 to 74 times greater than that in the general population. Because of the challenge of treating active tuberculosis after transplantation, every effort must be made to diagnose and treat active tuberculosis before transplantation. The standard short-course treatment for active tuberculosis is recommended in patients undergoing transplantation. The major difficulty in administering antituberculosis drugs to transplant patients is drug-drug interactions involving rifampin. Rifampin is a strong inducer of the microsomal enzymes that metabolize cyclosporine, tacrolimus, sirolimus, and corticosteroids. It may be difficult to maintain adequate levels of immunosuppressive drugs while using rifampin. Successful use of rifampin has been reported in transplant recipients, but the doses of cyclosporine, tacrolimus, and sirolimus must be increased at least two- to five-fold.

Solid-Organ Malignancy

There are no specific guidelines for the treatment of tuberculosis in patients with solid-organ malignancy. Standard treatment for tuberculosis is recommended in this population. Kim et al. reported that the radiographic and clinical treatment responses during anticancer chemotherapy were not clinically different between tuberculosis-infected patients with (n=24) and without (n=48) solid-organ malignancy.

Conclusion

Tuberculosis is still a significant public health concern in Korea. The growing elderly population with higher incidences of comorbidities has a risk of developing tuberculosis. Clinicians must monitor the side effects of and response to antituberculosis therapy in patients with comorbidities.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Park YK, Park YS, Na KI, Cho EH, Shin SS, Kim HJ. Increased tuberculosis burden due to demographic transition in Korea from 2001 to 2010. Tuberc Respir Dis 2013;74:104-10.
2. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. Seoul: Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2011.
3. Blumberg HM, Burman WJ, Chaissong RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
4. World Health Organization. Treatment of tuberculosis guideline. 4th ed. Geneva: World Health Organization; 2010.
5. Lee BJ, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005;127:1304-11.
6. Park WB, Kim W, Lee KL, Yim JJ, Kim M, Jung YJ, et al. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infect 2010;61:323-9.
7. British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, Davies P, Doffman S, Drobniewski F, et al. Guidelines for the pre-

Table 3. Recommended dose of first-line drugs in patients with chronic kidney disease (CKD)*

| Drug         | Stage 1–3 CKD† | Stage 4 and 5 CKD‡ |
|--------------|---------------|-------------------|
| Isoniazid    | 300 mg daily  | 300 mg daily      |
| Rifampicin   | <50 kg: 450 mg daily | <50 kg: 450 mg daily |
|              | ≥50 kg: 600 mg daily | ≥50 kg: 600 mg daily |
| Pyrazinamide | <50 kg: 1.5 g daily | 25–30 mg/kg three times per week |
|              | ≥50 kg: 2 g daily |                   |
| Ethambutol   | 15 mg/kg daily | 15–25 mg/kg three times per week (max 2.5 g) |
| Moxifloxacin | 400 mg daily  | Not suitable for three times weekly |

*Reproduced from British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee et al. Thorax 2010;65:557–70, with permission of BMJ Publishing Group Ltd. †Stage 1 CKD: normal creatinine clearance and function with urinary tract abnormality, Stage 2 CKD: creatinine clearance of 60–90 mL/min, Stage 3 CKD: creatinine clearance of 30–60 mL/min, Stage 4 CKD: creatinine clearance of 15–30 mL/min, Stage 5 CKD: creatinine clearance of <15 mL/min with or without dialysis.
vention and management of *Mycobacterium tuberculosis* infection and disease in adult patients with chronic kidney disease. Thorax 2010;65:557-70.

8. Subramanian AK, Morris MI; AST Infectious Diseases Community of Practice. *Mycobacterium tuberculosis* infections in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:68-76.

9. Kim DK, Lee SW, Yoo CG, Kim YW, Han SK, Shim YS, et al. Clinical characteristics and treatment responses of tuberculosis in patients with malignancy receiving anticancer chemotherapy. Chest 2005;128:2218-22.